ODTX (Odyssey Therapeutics) Notes Receivable: $0.00 Mil (As of Mar. 2026)


ODTX Odyssey Therapeutics Inc ODTX
9 GF Score
Price $19.23
! 2 Warning Signs
View Full Analysis

What is Odyssey Therapeutics Notes Receivable?

Odyssey Therapeutics ODTX +1.91% 9 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates ODTX with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Odyssey Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Odyssey Therapeutics Notes Receivable Related Terms

Odyssey Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Odyssey Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics Notes Receivable Chart

Odyssey Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Odyssey Therapeutics Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ODTX
9GF Score
Odyssey Therapeutics Inc ODTX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Odyssey Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Odyssey Therapeutics (ODTX) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Odyssey Therapeutics and its competitors.
Is Odyssey Therapeutics' Notes Receivable too high?
Odyssey Therapeutics' current Notes Receivable is $0.00 Mil. Overall, Odyssey Therapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' Notes Receivable compare to VOR and PHAT?
Odyssey Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Odyssey Therapeutics and its competitors. Odyssey Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Odyssey Therapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
9GF Score

Get the complete analysis for ODTX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.23
Price